Search

Current Market Outlook


The most bullish thing the stock market can do is go up, so by that measure, the market looks pretty bullish right here—most major indexes, advance-decline lines and a bunch of leading stocks have hit new highs in recent days, keeping the major trends pointed up. Short-term, things are a bit too quiet, so some wobbles wouldn’t shock us, but the next two or three weeks will likely see stocks being pushed and pulled by earnings season, which is getting underway now. All in all, our advice remains the same: Hold your strong stocks (though booking partial profits on the way up makes sense) and remain mostly invested, but for new buying, focus on stocks that have shown strong recent accumulation and look for decent entry points, especially if the firm is reporting earnings soon.

This week’s list has a bevy of potential leaders, including a few names that are trying to emerge from multi-month rest periods. Our Top Pick is Elastic (ESTC), an IPO from last year that’s racing up the right-hand side of a four-month consolidation. Start small and look for dips.

Stock Name	Price	Buy Range	Loss Limit
Beyond Meat (BYND)	132.87	155-162	124-129
Blackstone Group (BX)	49.12	43.5-46	40-41.5
Boston Beer Company (SAM)	459.16	370-380	340-346
Carvana (CVNA)	82.90	63-67	55.5-56.5
Cornerstone OnDemand (CSOD)	51.01	60-62	55.5-56.5
Dexcom (DXCM)	421.36	147.5-152.5	134-137
Elastic (ESTC)	86.17	90-93	81-83
Haemonetics (HAE)	136.59	117-121	107.5-109.5
Sarepta Therapeutics (SRPT)	120.93	149-154	134-137
Yeti Holdings (YETI)	42.80	30.5-32.5	27-28

Current Market Outlook


There remain some imperfections in the market’s armor, including a continued lack of pep from small- and mid-cap indexes. And there are still plenty of uncertainties, including the upcoming earnings season and the ongoing U.S.-China trade negotiation/battle. But you can always find things to worry about in the stock market—the key is to focus on a handful of time-tested indicators and let them guide you. For us, that involves the trends of the major indexes (intermediate- and longer-term trends are pointed up), the action of Top Ten stocks (vast majority look solid) and, to a lesser extent, sentiment (which remains neutral at best). You should still be following your loss limits and stops, and on the buy side, picking your stocks (and your spots) carefully, especially if something has earnings coming up in a couple of weeks. But overall, you should remain in a constructive stance.

Impressively, this week’s list has a nice batch of growth-oriented stocks with solid stories. Our Top Pick is Sunrun (RUN), which is a bit thin and wild, but has shown fantastic action lately and has a solid growth story.

Stock Name	Price	Buy Range	Loss Limit
Amarin (AMRN)	14.06	21.5-23.5	18-19.5
Arconic (ARNC)	17.00	24-25	22.5-23
Avalara (AVLR)	102.00	75-78	67.5-69
Baozun (BZUN)	44.24	50-52	43-45
First Solar (FSLR)	83.74	64.5-67	58.5-60.5
Illumina Inc. (ILMN)	289.74	360-370	330-335
MercadoLibre, Inc. (MELI)	980.83	605-630	545-565
Royal Gold, Inc. (RGLD)	129.66	99-102.5	90-92
Sunrun (RUN)	38.40	18.5-20	16-17
Zscaler (ZS)	126.22	80.5-83.5	71.5-73.5

This is a TOC.

As we begin the second half of the year, the odds continue to favor higher prices for the market down the road, so we remain in a generally bullish stance. Of course, the short-term will likely be news driven (trade talk, war fears and earnings season), but the big picture is looking sunny.
Individual growth stocks are a bit more divergent, with some looking tired but other, newer leaders looking peppy.

The broad market remains in fine health, with all major indexes trending higher and sentiment measures still bullish. Thus I continue to recommend that you be heavily invested in a diversified portfolio of stocks that fit your investment needs.

Today’s recommendation is a leader in its field, with great long-term growth prospects—as well as dependable recurring revenue—as the U.S. transitions away from fossil fuels to renewable energy sources.

As for the current portfolio, most of our stocks are doing great, but we’ve got to sell one, and it’s a tough choice. Details inside.

Today’s recommendation is another company tapping into the explosive growth in genomic testing. It makes diagnostic tests, which pits it against larger rivals like Illumina (ILMN) and Gardant Health (GH). But this small company plays in three very specific markets where its next-gen products are emerging as market leaders. And new collaborations with the likes of Johnson and Johnson (JNJ) and Loxo Oncology, now part of Eli Lilly (LLY), are further evidence that it’s on the right path. All the details are inside. Enjoy, and Happy 4th of July!

The big news today is that our Cabot Tides are now positive, telling us the market’s intermediate-term trend has once again turned up, and thus making all our market-timing indicators positive.

This morning we sent out a bulletin announcing this and discussing two new buys and you can read more about those in this issue.

This buying brings our cash position down to 23%, which is still high for a bull market, but we won’t rush; we’ll watch carefully to see where the real leaders are and guide you to increased investment in them in the weeks ahead.

The latest issue of Cabot Marijuana Investor is now available, with my current advice on the fourteen stocks in the portfolio.

The cannabis sector is currently in a correction, with both marijuana and CBD stocks trending lower, giving up some of their early-year gains—and perhaps building a bottom here.

In fact some of the biggest stocks, those supported best by institutional investors, are already looking stronger, though it will take time to know if they are in real uptrends. In the meantime, I continue to build cash, which will come in handy when it’s time to buy again.

Last week we sold a portion of three stocks and this week we’re selling portions of two more, raising the portfolio’s cash level to about 33%.

The action of the last couple of days has been a smack in the face for all investors, U.S. and emerging markets alike. As always, the Cabot growth disciplines tell us not to panic, but also not just to sit there and let the market take away your money. While we don’t have any changes to the portfolio tonight, this issue of Cabot Emerging Markets Investor shows a distinctly defensive tone, with a very heavy cash position and just two stocks rated Buy. We also have a new stock this week that’s perfectly suited to conditions. It’s a commodity play with a generous dividend, attractive valuation and a simple story. Read on for all the details.

The emerging market sector remains in a downtrend as we patiently await the buyers to arrive. When they do, we fully expect a profitable, sustained uptrend given the persistent decline this year, but until that happens, it’s best to stay mostly on the sideline.

There is one area in the EM world that’s doing well, though, and in tonight’s issue, our new recommendation is a mega-cap stock from that country. It’s a familiar name, is part of a resilient sector and has huge turnaround potential.

Current Market Outlook


The market continued to unravel last week, with leading growth stocks getting battered again and the rest of the market joining the downturn. In the near-term, we have seen some signs of panic and also some support, so it’s certainly possible the market can get off its duff a bit in the days ahead. But given the severity of the selling and the fact that the intermediate-term is firmly down, the odds favor more correction and consolidation ahead. That means the main goal here is the preservation of your capital and your confidence, both of which will come in handy during the next upturn. Nibbling on a name or two if you already hold a lot of cash is fine (we have some intriguing resilient situations in today’s issue) and could prove profitable if we bounce. But the big money will be made in the next sustained uptrend, so it’s best to stay mostly safe until that arrives.

This week’s list is a hodgepodge of stocks and sectors, which isn’t surprising given the environment. Our Top Pick is Ulta Beauty (ULTA), which remains resilient and looks ready to be a steady leader once the market correction is over.

Stock Name	Price	Buy Range	Loss Limit
Advanced Micro Devices (AMD)	82.24	25-26.5	22-23
Amarin (AMRN)	14.06	18-20	15-16
Callaway Golf (ELY)	20.21	22.5-23.5	20.5-21.5
Ensco plc (ESV)	6.52	8.0-8.5	7.0-7.3
Kirkland Lake Gold (KL)	51.30	20-21	18.4-18.9
Match (MTCH)	0.00	51-54	47-48
The Mosaic Company (MOS)	29.22	31.5-33	29.5-30.5
PBF Energy (PBF)	38.93	47.5-49.5	45-46
Petrobras (PBR)	14.78	14.5-15.5	13.5-14
Ulta Beauty (ULTA)	331.95	275-280	258-261

Growth stocks have gone over the cliff during the past eight trading days, with many suffering waterfall-like declines. With our Tides negative and most growth stocks in tatters, we’ve turned defensive by quickly paring back on our names.

Since last Monday, we’ve sold three stocks and taken partial profits on three more. And tonight, we’re selling another (Autodesk) -- all told, boosting our cash position from 16% a week and a half ago to 61% after tonight’s sale. From here, we’re likely to give some stocks a little rope given the chance of a short-term snap back, and because, big picture, we’re still in a bull market. But right now it’s time to focus on capital preservation.

In tonight’s issue, we give you all our latest thoughts on the market, our stocks and some names we see holding up so far (one of our favorites is written about starting on page 6). And we also talk a bit about what to do when everything falls apart at once, offering some pointers about differentiating what to hold and what to dump.

September has been tricky and tedious for growth stocks, with lots of volatility and some high-volume selloffs. It’s fair to say the evidence has worsened a bit, and we’ve placed a couple of stocks on hold and raised some mental stops.

That said, the majority of evidence is still bullish, very few growth stocks have actually broken down and the market’s trends are still positive. Net-net, then, we’re still mostly bullish, but are keeping our eyes open should things change.

In tonight’s issue, we introduce our new Real Money Index, which is replacing the Two-Second Indicator on page 8; we think it will help us lean against the wind in many circumstances. (We’ll still be following the Two-Second Indicator in house.) And we also take a deep dive into all of our stocks, letting you know what we’re thinking as many have consolidated of late.

The market continues to make progress, despite the dramatic headlines gracing the front page every day (and popping up online throughout the day). Today I’m adding a well-known restaurant stock to the Dividend Growth tier of our portfolio, to take advantage of rising consumer spending and the strong American economy. I also have updates on all our stocks, most of which are rated Buy, and at the end of the issue I take a look at the importance of diversification.